Status:
RECRUITING
Biological Mechanisms Behind Resynchronization Therapy in Heart Failure
Lead Sponsor:
Region Stockholm
Conditions:
Heart Failure
Cardiac Remodeling, Ventricular
Eligibility:
All Genders
18-80 years
Brief Summary
Heart failure is a common disease, affecting 2-3% of the population in the western world. About 30% of patients with heart failure and reduced ejection fraction display signs of electrical dyssynchron...
Detailed Description
In dyssynchrony the conduction of electrical signals within the heart is prolonged causing a delay between the activation and contraction of septum and lateral left ventricular wall. In turn, this res...
Eligibility Criteria
Inclusion
- Ejection fraction (EF) = or \< 35% and A or B
- A) Left bundle branch block (LBBB) QRS = or \> 150 ms or a high proportion ventricular pacing and planned for CRT at Karolinska University Hospital.
- B) Planned for medical treatment and followed at Karolinska University Hospital.
- Ability to understand the given information.
- Ability to give informed consent.
Exclusion
- Pregnant or planning pregnancy
- Not able to give informed consent -
Key Trial Info
Start Date :
March 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT06140914
Start Date
March 15 2023
End Date
March 1 2026
Last Update
November 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Universitetssjukhuset
Stockholm, Sweden, 171 76